AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 62 min read$SXTP

60 Degrees Pharmaceuticals to unblind hospitalized babesiosis study after enrolling 30; Jan 2027 readout planned

60 Degrees Pharmaceuticals (SXTP) will unblind its hospitalized babesiosis study after enrolling 30 patients. The company expects results in January 2027 and plans to discuss regulatory pathways with the FDA. No safety signals were identified, and an expanded-access study supports potential molecular cures.

Original reporting
tradingview.com
Published Oct 6, 2026, 11:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
60 Degrees Pharmaceuticals to unblind hospitalized babesiosis study after enrolling 30; Jan 2027 readout planned — source image
Source · tradingview.com
Decision brief

The 30-second read

$SXTPNeutralLow
01

Why it matters

The unblinding schedule sets a clear timeline for market participants to price in trial risk, making the Jan 2027 readout a focal point for short‑term trading strategies.

02

Market read

First disclosure of trial unblinding and data timeline; creates a near‑term catalyst for the stock.

03

What to watch

Regulatory timeline and potential need for additional enrollment could delay any positive catalyst beyond Jan 2027.

Relevance 8/10Novelty 8/10Timing: pre‑Jan 2027

Background

The company completed enrollment short of the planned 33 patients, citing minimal statistical benefit from additional subjects and seasonal recruitment constraints.

Company-level read

Ticker impact

$SXTPNeutralHigh confidence
Context

60 Degrees Pharmaceuticals announced it will unblind its hospitalized babesiosis study after enrolling 30 patients, with results expected in Jan 2027.

Expected impact

potential upside if data are positive; downside risk if endpoints are missed

Evidence & confidence

Biotech stocks typically move on trial readouts; the upcoming Jan 2027 data is a material catalyst.

Market effects

Sector

May influence other infectious‑disease biotech peers as a benchmark for babesiosis trials.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Low global impact; primarily relevant to investors tracking niche infectious‑disease pipelines.

Counterpoint

What could challenge this read

If the trial fails to meet endpoints, the stock could experience a sharp sell‑off despite prior optimism.

Key entities

  • company
    60 Degrees Pharmaceuticals

    Biopharma developing treatments for severe babesiosis.

Read at source← All news

Story60 Degrees to unblind severe babesiosis trial and seek FDA pre‑sNDA meeting in January 2027

Also covered by

2 outlets

Related articles

OCT 27
$SXTPMedAI 8/10

60 Degrees Reports Negative Babesia PCR Results In Completed Expanded Access Patients; Stock Down

60 Degrees Pharmaceuticals (SXTP) reported negative PCR results in 5 patients from its expanded access study of tafenoquine for babesiosis, with 4 also testing negative on a sensitive NAT test. All patients showed clinical improvement. The stock is down 29% to $0.60. The company expects to unblind a separate study in January 2027. Tafenoquine is not FDA-approved for babesiosis.

rttnews.com2 min
OCT 27
$SXTPMedAI 8/10

60 Degrees Pharmaceuticals (SXTP) Reports PCR-Negative Outcomes in 5 Babesiosis Patients

60 Degrees Pharmaceuticals (SXTP) reported that all 5 completed patients in its expanded access study showed clinical improvement and tested negative for Babesia via PCR, with 4/5 also NAT-negative post-treatment. The company may seek accelerated FDA approval using NAT nonreactivity as a surrogate. Two additional patients are currently being treated, with a total enrollment of 7. The study remains open pending potential FDA discussions.

tradingview.com1 min
OCT 27
$SXTPMedAI 8/10

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

60 Degrees Pharmaceuticals reported that all five patients in its expanded access study for relapsing babesiosis showed significant improvement and tested negative for the parasite. Four of five patients also tested negative on highly sensitive NAT testing. The study evaluates tafenoquine-containing regimens and remains open with seven patients enrolled. The company plans to discuss potential FDA approval pathways.

stocktitan.net2 min
OCT 27
$SXTPMedAI 8/10

60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients

60 DEGREES PHARMACEUTICALS, INC. (SXTP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients ● All five completed patients (100%) reported much or very much improved clinical outcomes and tested negative for Babesia on

SEC EDGAR 8-K2 min